News and Trends 16 Jul 2024 German biotech raises $150M on its way to tackle cancer therapy resistance …events (TEAEs) being mild to moderate. Only a small percentage of patients experienced grade 3 or higher adverse events. Phil L’huillier, chief executive officer of CatalYm commented on these results…. July 16, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2025 First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field? …Labiotech. The bacteria that zosurabalpin is targeting is a deadly Gram-negative bacteria called Acinetobacter Baumannii. Gram-negative bacteria have a thick outer layer unlike Gram-positive bacteria, making them notorious to treat,… June 9, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Vicore reports new data from idiopathic pulmonary fibrosis study …data show C21 continues to be safe and well tolerated with no treatment-related serious adverse events, and that C21 continues to demonstrate long-term efficacy. At 36 weeks the average forced… May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored 20 Sep 2017 What you need to Know about the Legalization of Cannabis for Medical Use …a chain of unforeseeable events Germany has one of the strictest narcotic drugs laws in Europe. In my opinion, if the German Federal Administrative Court hadn’t made a very specific… September 20, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 New discovery “an area of cancer research with tremendous promise for breakthroughs” …ANKLE1. ANKLE1 acts on chromatin bridges trapped in the midzone of dividing cells. By cutting these bridges, ANKLE1 prevents damage to the genetic material and stops the immune system from… April 21, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2024 Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it Yesterday was a big day for European biotechs. As if CatalYm’s $150 million series D round wasn’t enough for one day, the Swiss biotech Asceneuron bagged $100 million in a… July 17, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2024 From LSD to healing minds: Where are we standing in psychedelic drug development? …enthusiasts who themselves had recreational experience with psychedelics before. “The initial response to this sector from the biotech industry was highly conservative. On the one hand, you had this set… March 13, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Hemophilia drug from Sanofi and Sobi has license application accepted for priority review by FDA …was well-tolerated, and inhibitor development to factor VIII was not detected. The most common treatment-emergent adverse events which was less than 5% of participants overall were headache, arthralgia, fall, and… August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Amolyt Pharma publishes hypoparathyroidism treatment results …the findings in bone biomarkers, bone mineral density (BMD) was stable, including in patients with osteopenia. AZP-3601 was well tolerated with no serious adverse events. There were only mild to… October 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2017 Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene …of new, targeted therapies. PTEN is a known tumour suppressor gene, meaning it keeps cell growth under control and prevents cancer. It manages this by regulating the levels of phosphatidylinositol-3,4,5-trisphosphate… October 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Encouraging results from respiratory diseases vaccine trial …IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no vaccine-related serious adverse events (SAEs)…. June 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques… January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email